Author

Aileen L Pangan

ASSOCIATION BETWEEN PROPOSED DEFINITIONS OF CLINICAL REMISSION/RESPONSE AND WELL-BEING IN PATIENTS WITH CROHN'S DISEASE

William Sandborn, James D Lewis, Julian Panés, Edward V. Loftus, Jr, Geert R. D'Haens, ZHUQING YU, Bidan Huang, Ana P. Lacerda, Aileen L Pangan, Brian G. Feagan

PATIENT-REPORTED OUTCOMES WITH UPADACITINIB IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: PHASE 2 RESULTS FROM CELEST STUDY

Laurent Peyrin-Biroulet, Edouard Louis, Edward V Loftus Jr, Namita Tundia, Mahesh Fuldeore, Ana P. Lacerda, Jeffrey Enejosa, Aileen L Pangan

SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM CELEST

William J Sanborn, Brian G. Feagan, Julian Panés, Geert R. D'Haens, Jean-Frederic Colombel, Qian Zhou, Bidan Huang, J. V. Enejosa, Aileen L Pangan, Ana P. Lacerda

Item 1 - 3 / 3
1